Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
1994 3
1995 3
1996 3
1997 2
1998 2
1999 4
2000 6
2001 11
2002 19
2003 22
2004 35
2005 33
2006 54
2007 67
2008 84
2009 110
2010 123
2011 129
2012 170
2013 169
2014 204
2015 210
2016 174
2017 172
2018 185
2019 190
2020 174
2021 187
2022 176
2023 144
2024 145
2025 179
2026 67

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,850 results

Results by year

Filters applied: . Clear all
Page 1
Cancer prevention with rapamycin.
Blagosklonny MV. Blagosklonny MV. Oncotarget. 2023 Apr 14;14:342-350. doi: 10.18632/oncotarget.28410. Oncotarget. 2023. PMID: 37057884 Free PMC article.
Rapamycin (sirolimus) and other rapalogs (everolimus) are anti-cancer and anti-aging drugs, which delay cancer by directly targeting pre-cancerous cells and, indirectly, by slowing down organism aging. ...In several dozen murine models, rapam …
Rapamycin (sirolimus) and other rapalogs (everolimus) are anti-cancer and anti-aging drugs, which delay cancer b …
MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.
Laberge RM, Sun Y, Orjalo AV, Patil CK, Freund A, Zhou L, Curran SC, Davalos AR, Wilson-Edell KA, Liu S, Limbad C, Demaria M, Li P, Hubbard GB, Ikeno Y, Javors M, Desprez PY, Benz CC, Kapahi P, Nelson PS, Campisi J. Laberge RM, et al. Nat Cell Biol. 2015 Aug;17(8):1049-61. doi: 10.1038/ncb3195. Epub 2015 Jul 6. Nat Cell Biol. 2015. PMID: 26147250 Free PMC article.
We show that rapamycin selectively blunts the pro-inflammatory phenotype of senescent cells. Cellular senescence suppresses cancer by preventing cell proliferation. ...Thus, rapamycin might ameliorate age-related pathologies, including late-life can …
We show that rapamycin selectively blunts the pro-inflammatory phenotype of senescent cells. Cellular senescence suppresses cancer …
Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer.
Chambers MS, Rugo HS, Litton JK, Meiller TF. Chambers MS, et al. J Am Dent Assoc. 2018 Apr;149(4):291-298. doi: 10.1016/j.adaj.2017.10.024. Epub 2018 Feb 10. J Am Dent Assoc. 2018. PMID: 29439772 Review.
BACKGROUND: Patients with metastatic breast cancer may develop oral morbidities that result from therapeutic interventions. Mammalian target of rapamycin (mTOR) inhibitor-associated stomatitis (mIAS) is a common adverse event (AE), secondary to mTOR inhibitor therap …
BACKGROUND: Patients with metastatic breast cancer may develop oral morbidities that result from therapeutic interventions. Mammalian …
Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage.
Dao V, Pandeswara S, Liu Y, Hurez V, Dodds S, Callaway D, Liu A, Hasty P, Sharp ZD, Curiel TJ. Dao V, et al. Cancer Prev Res (Phila). 2015 May;8(5):400-9. doi: 10.1158/1940-6207.CAPR-14-0313-T. Epub 2015 Mar 3. Cancer Prev Res (Phila). 2015. PMID: 25736275 Free PMC article.
Cancer prevention is a cost-effective alternative to treatment. In mice, the mTOR inhibitor rapamycin prevents distinct spontaneous, noninflammatory cancers, making it a candidate broad-spectrum cancer prevention agent. ...Thus, we …
Cancer prevention is a cost-effective alternative to treatment. In mice, the mTOR inhibitor rapamycin prevents d …
Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial.
DeMichele A, Clark AS, Shea E, Bayne LJ, Sterner CJ, Rohn K, Dwyer S, Pan TC, Nivar I, Chen Y, Wileyto P, Berry LR, Deluca S, Savage J, Makhlin I, Pant DK, Martin H, Egunsola A, Mears N, Goodspeed BL, Chislock EM, Graves J, Wang J, Shih N, Belka GK, Berry D, Nayak A, Feldman M, Chodosh LA. DeMichele A, et al. Nat Med. 2025 Oct;31(10):3464-3474. doi: 10.1038/s41591-025-03877-3. Epub 2025 Sep 2. Nat Med. 2025. PMID: 40897974 Clinical Trial.
Breast cancer recurrence may arise from dormant disseminated tumor cells (DTCs) that persist in bone marrow and other sites. Clinically, DTCs are independently associated with breast cancer recurrence and death. Preclinical studies in mouse models identified autopha …
Breast cancer recurrence may arise from dormant disseminated tumor cells (DTCs) that persist in bone marrow and other sites. Clinical …
Temsirolimus.
Schulze M, Stock C, Zaccagnini M, Teber D, Rassweiler JJ. Schulze M, et al. Recent Results Cancer Res. 2014;201:393-403. doi: 10.1007/978-3-642-54490-3_24. Recent Results Cancer Res. 2014. PMID: 24756806 Review.
Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase mammalian target of rapamycin (mTOR) and consequently blocks the translation of cell cycle regulatory proteins and prevents overexpression of angiogenic growth factors. .. …
Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase mammalian target of rapamycin (mTOR) a …
Mammalian target of rapamycin inhibitors for prolonged secondary prevention of nonmelanoma skin cancer in solid organ transplant recipients.
Gluck M, Hodak E, Davidovici B. Gluck M, et al. Dermatol Ther. 2022 Aug;35(8):e15649. doi: 10.1111/dth.15649. Epub 2022 Jun 29. Dermatol Ther. 2022. PMID: 35716099
Immunosuppressive agents are essential for graft survival in solid-organ transplant recipients (SOTRs), but they have substantial durable side effects, including a higher incidence of aggressive nonmelanoma skin cancers (NMSCs). Hitherto, only one class of immunosuppressan …
Immunosuppressive agents are essential for graft survival in solid-organ transplant recipients (SOTRs), but they have substantial durable si …
Prevention of cancer by inhibiting aging.
Blagosklonny MV. Blagosklonny MV. Cancer Biol Ther. 2008 Oct;7(10):1520-4. doi: 10.4161/cbt.7.10.6663. Epub 2008 Oct 21. Cancer Biol Ther. 2008. PMID: 18769112 Free article. Review.
As recently proposed, the nutrient-sensing TOR (target of rapamycin) pathway is involved in cellular and organismal aging. In rodents, certain conditions that interfere with the TOR pathway slow aging and prevent cancer. Retrospective analysis of clinical dat …
As recently proposed, the nutrient-sensing TOR (target of rapamycin) pathway is involved in cellular and organismal aging. In rodents …
Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin.
Popovich IG, Anisimov VN, Zabezhinski MA, Semenchenko AV, Tyndyk ML, Yurova MN, Blagosklonny MV. Popovich IG, et al. Cancer Biol Ther. 2014 May;15(5):586-92. doi: 10.4161/cbt.28164. Epub 2014 Feb 20. Cancer Biol Ther. 2014. PMID: 24556924 Free PMC article.
Target of Rapamycin (TOR) is involved in cellular and organismal aging. Rapamycin extends lifespan and delays cancer in mice. ...In Rap-4 group, mean lifespan extension was achieved without significant cancer prevention. The complex relationship …
Target of Rapamycin (TOR) is involved in cellular and organismal aging. Rapamycin extends lifespan and delays cancer in …
Temsirolimus.
Stock C, Zaccagnini M, Schulze M, Teber D, Rassweiler JJ. Stock C, et al. Recent Results Cancer Res. 2010;184:189-97. doi: 10.1007/978-3-642-01222-8_13. Recent Results Cancer Res. 2010. PMID: 20072839 Review.
Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase mammalian target of rapamycin and consequently blocks the translation of cell cycle regulatory proteins and prevents overexpression of angiogenic growth factors. ...
Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase mammalian target of rapamycin and cons …
2,850 results